Comparative evaluation of isosorbide mononitrate and alendronate in management of
postmenopausal osteoporosis.
Author(s): Duhan N, Siwach RC, Yadav K, Dahiya K, Nanda S, Sirohiwal D.
Affiliation(s): Department of Obstetrics and Gynecology, Pt. B.D. Sharma PGIMS, H. No. 6/9J,
Medical Campus, Rohtak, 124001 Haryana, India. nkadian@gmail.com
Publication date & source: 2012, Arch Gynecol Obstet. , 285(4):1019-23
BACKGROUND: Osteoporosis, a skeletal disorder that adversely affects bone
strength , is common among postmenopausal women primarily due to reduced ovarian
estrogens.
PURPOSE: The present study was taken up to evaluate the role of isosorbide
mononitrate (IMN) in the management of postmenopausal osteoporosis and to compare
its efficacy with that of alendronate.
METHODS: This prospective systematic randomized study was conducted on 90
postmenopausal women with lumbar spine BMD >2.5 SD below the young adult
reference range. The participants received either Tab Alendronate 70 mg orally,
once weekly (Group I) or Tab IMN 40 mg orally once daily (Group II) for 9 months,
in addition to 500 mg of oral calcium daily. The BMD of the lumbar spine was
measured using DEXA scan at enrolment and after 9 months. The data was analyzed
by Student's t test and Chi-square test.
RESULTS: The mean baseline BMD was 0.67 + 0.097 and 0.68 + 0.067 g/cm(2) in Group
I and II, respectively. An increase of 11.94% in the mean BMD was noted after 9
months of treatment with alendronate as against 8.82% with IMN. Headache,
flushing and palpitations in Group II and nausea, epigastric pain and heart burn
in Group I were the most common adverse effects.
CONCLUSION: IMN has a beneficial effect on bone turnover in cases of
postmenopausal osteoporosis and that the effect is comparable to that of
alendronate. IMN is a promising and safe alternative to alendronate for the
management of postmenopausal osteoporosis.
|